1-3 of 3
Darejan Ghirdaladze
Close
Sort by
Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1507.
https://doi.org/10.1182/blood.V120.21.1507.1507
Published: 2012
Journal Articles

AC220, a Potent, Selective, Second Generation FLT3 Receptor Tyrosine Kinase (RTK) Inhibitor, in a First-in-Human (FIH) Phase 1 AML Study.

Jorge Cortes, MD, James Foran, MD, Darejan Ghirdaladze, MD, PhD, Marcel P DeVetten, MD, Mamia Zodelava, MD, PhD, Peter Holman, MD, Mark J Levis, MD, PhD, Hagop M Kantarjian, MD, Gautam Borthakur, MD, Joyce James, PhD, Patrick P Zarringkar, PhD, Ruwanthi N Gunawardane, PhD, Robert C Armstrong, PhD, Norman M Padre, Wendell Wierenga, PhD, Robert Corringham, MD, Mohit Trikha, PhD
Journal: Blood
Blood (2009) 114 (22): 636.
https://doi.org/10.1182/blood.V114.22.636.636
Published: 2009
Journal Articles

Phase 1 AML Study of AC220, a Potent and Selective Second Generation FLT3 Receptor Tyrosine Kinase Inhibitor

Jorge E. Cortes, Darejan Ghirdaladze, James M. Foran, Marcel P. DeVetten, Mamia Zodelava, Mark J. Levis, Norman M. Padre, James Joyce, Patrick P. Zarrinkar, Robert Corringham
Journal: Blood
Blood (2008) 112 (11): 767.
https://doi.org/10.1182/blood.V112.11.767.767
Published: 2008